Kim BH - Search Results

1

Surgical resection versus ablation for early hepatocellular carcinoma: The debate is still open.

Kim BH. Kim BH. Clin Mol Hepatol. 2022 Apr;28(2):174-176. doi: 10.3350/cmh.2021.0400. Epub 2022 Jan 26. Clin Mol Hepatol. 2022. PMID: 35078307 Free PMC article. No abstract available.

2

Low P2/MS value is an independent risk factor for early recurrence of hepatocellular carcinoma after radiofrequency ablation therapy.

Kwak MS, Lee JH, Chung GE, Yu SJ, Jung EU, Kim BH, Choi DH, Kim HY, Kim SH, Lee JM, Lee JY, Kim YJ, Yoon JH, Lee HS. Kwak MS, et al. Among authors: kim hy, kim yj, kim sh, kim bh. Hepatogastroenterology. 2011 Jan-Feb;58(105):147-52. Hepatogastroenterology. 2011. PMID: 21510303

3

Validation of a model to estimate survival in ambulatory patients with hepatocellular carcinoma: a single-centre cohort study.

Kim BH, Park JW, Nam BH, Kwak HW, Kim WR. Kim BH, et al. Among authors: kim wr. Liver Int. 2014 Aug;34(7):e317-23. doi: 10.1111/liv.12519. Epub 2014 Mar 24. Liver Int. 2014. PMID: 24606128 Free PMC article.

4

A model predicting survival of patients with recurrent or progressive hepatocellular carcinoma: the MORE score.

Choi SI, Yu A, Kim BH, Ko EJ, Park SS, Nam BH, Park JW. Choi SI, et al. Among authors: kim bh. J Gastroenterol Hepatol. 2017 Mar;32(3):651-658. doi: 10.1111/jgh.13532. J Gastroenterol Hepatol. 2017. PMID: 27519171

5

Temporal improvement in survival of patients with hepatocellular carcinoma in a hepatitis B virus-endemic population.

Kim BH, Lim YS, Kim EY, Kong HJ, Won YJ, Han S, Park S, Hwang JS. Kim BH, et al. Among authors: kim ey. J Gastroenterol Hepatol. 2018 Feb;33(2):475-483. doi: 10.1111/jgh.13848. J Gastroenterol Hepatol. 2018. PMID: 28612951

6

Epidemiology of liver cancer in South Korea.

Kim BH, Park JW. Kim BH, et al. Clin Mol Hepatol. 2018 Mar;24(1):1-9. doi: 10.3350/cmh.2017.0112. Epub 2017 Dec 18. Clin Mol Hepatol. 2018. PMID: 29249129 Free PMC article. Review.

7

Long-term prognostic impact of osteopontin and Dickkopf-related protein 1 in patients with hepatocellular carcinoma after hepatectomy.

Byeon H, Lee SD, Hong EK, Lee DE, Kim BH, Seo Y, Joo J, Han SS, Kim SH, Park SJ. Byeon H, et al. Among authors: kim sh, kim bh. Pathol Res Pract. 2018 Jun;214(6):814-820. doi: 10.1016/j.prp.2018.05.002. Epub 2018 May 6. Pathol Res Pract. 2018. PMID: 29753515

8

Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.

Park JW, Kim YJ, Kim DY, Bae SH, Paik SW, Lee YJ, Kim HY, Lee HC, Han SY, Cheong JY, Kwon OS, Yeon JE, Kim BH, Hwang J. Park JW, et al. Among authors: kim yj, kim hy, kim dy, kim bh. J Hepatol. 2019 Apr;70(4):684-691. doi: 10.1016/j.jhep.2018.11.029. Epub 2018 Dec 6. J Hepatol. 2019. PMID: 30529387 Free article. Clinical Trial.

9

Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma.

Kim BH, Park JW, Kim JS, Lee SK, Hong EK. Kim BH, et al. Among authors: kim js. Gut Liver. 2019 May 15;13(3):342-348. doi: 10.5009/gnl18345. Gut Liver. 2019. PMID: 30600675 Free PMC article.

10

How long should physicians follow up with patients after curative treatment for hepatocellular carcinoma?

Kim BH. Kim BH. Clin Mol Hepatol. 2020 Oct;26(4):579-581. doi: 10.3350/cmh.2020.0200. Epub 2020 Sep 23. Clin Mol Hepatol. 2020. PMID: 32962329 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,171 results

Search Page